GlassScriptPhysician profile
Patrick L Mccurdy
NPI 1295024669
$312.32
in general payments reported to CMS, 2019-2025
12 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $183 · 2022: $129.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $96.97 | 2021-2022 | |
| Abbvie INC. | $40.85 | 2021-2022 | |
| Almatica Pharma LLC | $21.71 | 2021 | |
| Novartis Pharmaceuticals Corporation | $21.08 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $19.44 | 2022 | |
| Ironshore Pharmaceuticals INC. | $18.75 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $18.72 | 2021 | |
| Horizon Therapeutics Plc | $16.83 | 2021 | |
| Therapeuticsmd, INC. | $16.04 | 2021 | |
| Lilly USA, LLC | $15.03 | 2021 | |
| Merck Sharp & Dohme LLC | $13.52 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $13.38 | 2022 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patrick Mccurdy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.